Most hedge funds diversify aggressively.
Abrams Capital does almost the exact opposite.
Current portfolio:
• 12 positions
• ~40% in Loar Holdings
• No meaningful leverage
• Historically around 15% annualized returns
Curious whether investors here view this as conviction—or concentration risk taken too far?
Full breakdown here.
Scientists recently ruled out technosignatures from 3I/ATLAS.
Probably just a comet.
Still, we now live in a world where:
• Interstellar objects are routinely detected.
• SETI can analyze tens of millions of signals.
• Oumuamua remains one of astronomy's great mysteries.
Maybe the coolest part isn't finding aliens.
Maybe it's becoming the kind of civilization capable of looking.
Feel free to visit here for more but it's mostly made by humans -- no aliens yet.
Interesting IPO.
Highlights:
⚛️ $1.68B raised
💰 $24M insider buying
🚀 99.9% gate fidelity
🤖 Quantum AI ambitions
🏦 JPMorgan partnership
✈️ Airbus collaboration
But also:
❌ ~$300M annual losses
❌ Tiny revenues
❌ Minimal trading history
Curious where people stand on quantum computing as an investment and this one opportunity in particular.
Interesting question.
The usual suspects dominate:
🇺🇸 United States
🇨🇳 China
🇬🇧 United Kingdom
🇮🇱 Israel
But what's fascinating is how differently each approaches cybersecurity.
Meanwhile, AI, ransomware, supply-chain attacks, and quantum computing are creating entirely new challenges.
I recently put together a deep dive covering:
• Top cyber economies
• Unit 8200
• AI-powered attacks
• Ransomware
• Quantum threats
• Zero Trust security
Curious where people think the cyber landscape will be in 10 years.
I've been researching Erie Indemnity (ERIE).
A few things stood out:
• Rare insider purchase worth ~$1.4M
• Dividend Aristocrat
• 59% below ATH
• Short interest near 10%
• Days-to-cover almost 12
• Unique fee-based insurance model
It's not statistically cheap, but it's also not a traditional insurer taking massive underwriting risk.
Curious what everyone thinks:
Quality compounder temporarily out of favor?
Or still too expensive?
Full write-up here.
Revolution Medicines recently reported Phase 3 data for daraxonrasib in metastatic pancreatic cancer.
Key numbers:
• 13.2 months median survival vs 6.7 months
• Hazard ratio: 0.40
• Better quality of life
• Fewer treatment discontinuations
For context, pancreatic cancer remains one of the deadliest major cancers.
What I found equally interesting was the investing side:
• RVMD went from roughly $15 to $156
• Institutions stayed heavily involved
• Oncology-focused director Thilo Schroeder accumulated stock for years
• Many investors panicked during a 40% drawdown in 2023
The science is obviously the important part.
But it's also a fascinating case study in biotech investing.
Full breakdown here.
Following reports surrounding the death of Persepolis creator Marjane Satrapi, I researched the science behind:
• Takotsubo cardiomyopathy (Broken Heart Syndrome)
• The widowhood effect
• Why severe grief can affect physical health
Also revisited Persepolis, which remains one of the most remarkable animated films ever made.
Curious whether anyone here has encountered these concepts personally or professionally.
Breakdown here for more.
The new Obama Presidential Center officially opens to the public this month in Chicago.
Highlights include:
• Life-sized Oval Office replica
• Fully digital museum experience
• Community basketball court
• Michelle Obama's garden
• Public gathering spaces
Admission is $30, making it the most expensive presidential museum ticket in the U.S.
I put together a breakdown of the museum plus a broader guide to Chicago attractions.
Curious what Chicago locals think.
Worth the ticket price?
Interesting insider purchase here.
Meyer Malka (Ribbit Capital founder and Robinhood director) recently purchased roughly $35 million worth of HOOD shares.
Meanwhile:
• Assets reached $307B
• Gold subscribers hit 4.3M
• Net income was $346M
• Short interest remains low
The business looks significantly stronger than it did a few years ago.
The real debate is valuation.
Would love to hear both bullish and bearish takes.
Full write-up here.
Most people think of humor as entertainment.
But a growing body of evidence suggests laughter may:
• Reduce stress
• Improve resilience
• Strengthen relationships
• Help us navigate adversity
I wrote a light-hearted piece exploring why a healthy sense of humor may actually be one of life's most valuable investments.
Plus:
• 3 terrible jokes
• Tax humor
• A surprisingly serious message
Do you think humor is something people can intentionally develop?
Summit Therapeutics caught my attention for a few reasons:
• Ivonescimab is attempting to compete against Keytruda
• Multiple insiders recently purchased shares
• Baker Bros. owns a major stake
• Short interest is roughly 23% of float
• FDA decision expected November 14, 2026
The company remains pre-revenue and speculative, but the risk/reward profile is increasingly interesting.
Full breakdown here.
Curious what others think: future oncology winner or overhyped biotech?
Norwegian Cruise Line Holdings caught my attention because the setup is pretty unusual.
Recent highlights:
• Stephen Pagliuca, former Bain Capital leader, bought roughly $25M of stock
• New CEO John Chidsey also bought more than $2.5M
• Several other directors bought shares too
• Institutional ownership appears extremely high, with nearly the full float controlled by institutions
• Short interest is elevated
• Forward P/E is under 10x
• Q1 showed revenue growth and EBITDA improvement, but guidance was lowered
The bull case: insider conviction, cost-cutting, new leadership, cheap valuation, cruise demand recovery.
The bear case: debt, fuel costs, consumer weakness, macro/geopolitical risk, and cruise-industry cyclicality.
I wrote a fuller FUNanc1al breakdown here.
Curious how others see it: legitimate turnaround, value trap, or “wait and see”?
David Koepp recently stated that alien life is a "mathematical certainty."
Maybe.
Maybe not.
Personally, I find the most fascinating part isn't whether aliens exist.
It's that we're still asking the question.
Steven Spielberg is nearly 80 and still making movies about wonder, possibility, and imagination.
Whether extraterrestrials exist or not, curiosity remains one of humanity's greatest strengths.
Would love to hear your thoughts:
Do you believe intelligent life exists elsewhere?
Or is the mystery itself the most beautiful part?
Interesting setup.
Incoming CEO Mike Weinbach purchased approximately $5.8M worth of shares immediately after joining the company.
Meanwhile:
• Forward P/E: ~6.6
• P/B: ~0.93
• Dividend Yield: ~3%
• Book Value growing
• Recently completed a $1.7B acquisition transforming the company beyond traditional mortgage insurance.
Curious whether the market is underestimating the significance of the Inigo acquisition.
Full write-up here.
What am I missing?
#ValueInvesting
Interesting moves from Third Point:
• Amazon remains largest disclosed position
• New stake in GLD
• New stake in Hut 8
• Added Alphabet and Meta
• Reduced Nvidia exposure
• Long-term annualized return since inception around 13.2%
Do you think activist investing still has an edge in today's market?
Full breakdown here.
Clint Eastwood is 96.
Warren Buffett is 95.
Mick Jagger is still touring.
David Attenborough is still making documentaries.
Maybe retirement isn't the goal.
Maybe purpose is.
Interesting thought:
As Louis Armstrong once said:
"Musicians don't retire; they stop when there's no more music in them."
Full reflection here.
Interesting setup.
Bull case:
• First insider purchase in company history
• Former Hong Kong Exchange CEO bought nearly $1M worth
• AI-native transformation underway
• Operating cash flow +246%
• $125M buyback authorization
• Institutions own >100% of float
Bear case:
• IT spending slowdown
• Class-action lawsuit overhang
• Slower growth than historical levels
• Consulting sector pressure
At ~7x forward earnings, the valuation appears unusually compressed for an AI-enabled digital transformation company.
Curious what the community thinks.
Full breakdown here.
Interesting observation:
Most companies don't have large AI departments.
Typically:
🧠 1–5% build AI
👥 20–50% use AI
Yet AI is already changing:
• Hiring
• Startups
• Productivity
• Cost structures
• Competitive advantages
The real question isn't whether AI will matter.
It's how quickly organizations adapt.
Full analysis here.
Interesting biotech setup:
🧬 Director bought ~$3.3 million worth of stock
🏦 Institutions own more than 100% of float
🐻 Short interest ~15.9%
📊 Phase 3 Geographic Atrophy data expected Q4 2026
💰 Cash runway into 2027
Bear case:
• Clinical failure
• Dilution
• Cash burn
Bull case:
• Multiple late-stage assets
• Potential regulatory approvals
• Strong institutional support
Curious how biotech investors view this one.
Full breakdown here.
Interesting setup developing in CDW:
• Director bought ~$2 million of stock
• CEO added shares despite previously buying at much higher prices
• Forward P/E around 11.2x
• Institutions effectively own the entire float
• Shares remain over 50% below ATH
Curious what others think.
Value trap?
Or overlooked technology infrastructure compounder?
Full breakdown here.